{
    "nctId": "NCT01855607",
    "briefTitle": "Topical Menthol for the Treatment of Chemotherapy Induced Peripheral Neuropathy",
    "officialTitle": "Topical Menthol for Chemotherapy Induced Peripheral Neuropathy (CIPN): A Randomized, Placebo Controlled Phase II Trial",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Cancer, Colon Cancer, Neuropathy",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "SUPPORTIVE_CARE",
    "enrollmentCount": 12,
    "primaryOutcomeMeasure": "Change in Brief Pain Inventory-Short Form Score",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Age\u226521 years\n2. History of stage I-III breast, gastrointestinal or gynecologic cancer\n3. Must have received at least one taxane or platinum based chemotherapy drug within two years prior to enrollment.\n4. Must exhibit a typical symptom of CIPN that was not present prior to chemotherapy. Symptoms include numbness, tingling, thermal hyperalgesia, cold allodynia in the hands and/or feet, muscle weakness or unsteady gait in at least two of the last seven days prior to registration.\n5. Signed informed consent\n6. Concomitant biologic, hormonal, or radiation therapy are acceptable\n7. Narcotics, antidepressants or other medications for the treatment of CIPN are permitted, if patient on a stable dose for at least one month prior to enrollment\n\nExclusion Criteria:\n\n1. Previous treatment with topical menthol (menthol/methylsalicylate products like BenGay, Aspercreme, or Icy Hot) of any concentration within the previous 3 months\n2. Known diabetic neuropathy\n3. Severe concomitant illnesses\n4. Known allergy or preexisting skin disease which prohibits use of menthol\n5. Any topical treatment for neuropathy or other serious skin condition on the hands or feet.",
    "sex": "ALL",
    "minimumAge": "21 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}